| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.08. | Vaso Corporation Announces Financial Results for Second Quarter of 2026 | 433 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a business portfolio in professional sales services and proprietary non-invasive... ► Artikel lesen | |
| 03.08. | Vaso Corporation Completes Sale of NetWolves Network Services to COEO Solutions | 306 | GlobeNewswire (Europe) | Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact:Jonathan NewtonInvestor RelationsPhone: 516-997-4600Email: jnewton@vasocorporation.com... ► Artikel lesen | |
| 31.07. | VASO Corp - 8-K, Current Report | 1 | SEC Filings | ||
| VASO Aktie jetzt für 0€ handeln | |||||
| 23.07. | Vaso Corporation beruft Shaun McMeans in den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| 23.07. | Vaso appoints Shaun McMeans to board of directors | 1 | Investing.com | ||
| 23.07. | Vaso Corporation Appoints Shaun McMeans to Board of Directors | 224 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., July 23, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional... ► Artikel lesen | |
| 23.07. | VASO Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 30.06. | VASO Global Raises Over £5M in Venture, Grant, and Debt Funding Round | 1 | FinSMEs | ||
| 30.06. | VASO Global wins support for recycled glass panels | 1 | The Construction Index | ||
| 15.05. | Vaso Corporation Announces Financial Results for First Quarter of 2026 | 457 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., May 15, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional... ► Artikel lesen | |
| 08.05. | VASO Corp - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year 2025 | 252 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional... ► Artikel lesen | |
| 17.12.25 | Vaso Corporation Announces Fifth Extension of Sales Representation Agreement with GE HealthCare | 482 | GlobeNewswire (Europe) | Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact:Jonathan NewtonInvestor RelationsPhone: 516-997-4600 Email: jnewton@vasocorporation.com... ► Artikel lesen | |
| 19.11.25 | NANO-X IMAGING LTD: Nanox Reaches Agreement with Vaso Corporation to Acquire VasoHealthcare IT, Accelerating U.S. Rollout of AI Solutions | 620 | GlobeNewswire (Europe) | PETACH TIKVA, Israel, Nov. 19, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that the parties... ► Artikel lesen | |
| 14.11.25 | Vaso Corporation Announces Financial Results for Third Quarter of 2025 | 396 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ASTRAZENECA | 156,00 | -0,22 % | JPMORGAN stuft ASTRAZENECA auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Astrazeneca mit einem Kursziel von 16000 Pence auf "Overweight" belassen. Die auf dem ESMO-Kongress präsentierten Studiendaten... ► Artikel lesen | |
| EYEPOINT | 0,370 | +6,32 % | XETR US30233G2093: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 39,660 | -0,03 % | DelveInsight Business Research, LLP: Severe Hypertriglyceridemia Market Set for Growth During the Forecast Period (2026-2036) Following Approval of Ionis' TRYNGOLZA and Emergence of Novel Therapies | DelveInsight | Severe Hypertriglyceridemia Market Set for Growth During the Forecast Period (2026-2036) Following Approval of Ionis' TRYNGOLZA and Emergence of Novel Therapies | DelveInsight
The severe hypertriglyceridemia... ► Artikel lesen | |
| CSPC PHARMA | 0,929 | +2,01 % | CSPC PHARMA Initiates Phase I Clinical Trial in China for SYS6077 Injection for Treatment of Advanced Malignant Tumors | ||
| SELLAS LIFE SCIENCES | 8,960 | +1,13 % | Sellas falls as REGAL trial nears final analysis | ||
| MADRIGAL PHARMACEUTICALS | 390,20 | +2,15 % | B.Riley bekräftigt Kaufempfehlung für Madrigal Pharmaceuticals - Kursziel von 670 Dollar im Visier | ||
| ACADIA PHARMACEUTICALS | 18,385 | +2,59 % | ACADIA PHARMACEUTICALS INC - 8-K, Current Report | ||
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| OPUS GENETICS | 3,180 | 0,00 % | Opus Genetics appoints chief scientific officer, operations head | ||
| CHUGAI PHARMACEUTICAL | 37,740 | +1,53 % | Chugai Pharma Q3 Earnings Rise On Sales Growth; FY26 Outlook Unchanged | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK), reported revenue of JPY 1,068.1 billion for the nine months ended September 30, 2026, marking a 17.2% increase from the previous... ► Artikel lesen | |
| SAVARA | 4,486 | +1,04 % | Savara Inc.: Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 | -- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - August 13, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 3,060 | +4,08 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update | NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 2,958 | -2,57 % | XFRA NEW INSTRUMENTS AVAILABLE ON 28.10.2026 | The following instruments on XETRA do have their first trading 28.10.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 28.10.2026
Aktien
1 US59564R8640 Biodexa Pharmaceuticals... ► Artikel lesen | |
| NEURIZON THERAPEUTICS | 0,045 | 0,00 % | XFRA ECQ0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILNEURIZON THERAPEUTICS... ► Artikel lesen |